Abstract: The present invention relates to metformin for use in treating a patient, wherein the patient exhibits an increased level of GDF15 in response to metformin treatment; to methods of identifying a patient who will benefit or who will not benefit from metformin treatment; methods of treating a patient at risk of developing or suffering from a disease or disorder comprising administering therapeutically effective amount of metformin; methods of adapting the dosage of metformin; the usage of GDF15 as biomarker for identifying a patient who will benefit or who will not benefit from metformin treatment, kits for use in identifying a patient who will benefit from metformin treatment and the use of the kits, as well as methods of treating a patient or who will not benefit from metformin treatment.

Abstract: Embodiments are described for a method of reducing power consumption in source synchronous bus systems by reducing signal transitions in the system. Instead of sending clock and data valid signals, only the start and end of valid data packets are marked by clock signal transitions, or only a number of clock pulses that corresponds to number of data words is sent, or only a number transitions on clock signals are sent. The clock signal transitions may comprise either clock pulses or exclusively rising edge or falling edge transitions of the clock signal.

Abstract: Embodiments are described for a method of reducing power consumption in source synchronous bus systems by reducing signal transitions in the system. Instead of sending clock and data valid signals, only the start and end of valid data packets are marked by clock signal transitions, or only a number of clock pulses that corresponds to number of data words is sent, or only a number transitions on clock signals are sent. The clock signal transitions may comprise either clock pulses or exclusively rising edge or falling edge transitions of the clock signal.